Latest news with #DiGeorge
Newsweek
5 days ago
- General
- Newsweek
In Neutral World War II Sweden, One American Couple Found Love
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Stockholm was among the most romantic places to be in Europe during World War II, according to Pat DiGeorge. It's where her parents, Herman Allen and Hedvig Johnson Allen, met in 1944, she said in an interview with Newsweek. Their story is one of the great romances of World War II. Between the uncertainty and global conflict, many soldiers, like her father, made lifelong connections during their time abroad. DiGeorge chronicled their love story in her book Liberty Lady: A True Story of Love and Espionage in WWII Sweden and spoke with Newsweek about how the war brought her parents together in the Swedish capital. Before her venture to Sweden, Hedvig Johnson Allen had recently graduated from secretarial school and was working in Washington, D.C. After a brief stint at IRS, which she found to be boring, she found work at the Office of Strategic Services (OSS). She was sent to London in early 1944 and remained there until August, when she was sent to Sweden, DiGeorge said. Count Folke Bernadotte, Hevdig Johnson Allen and Herman Allen appear in Stockholm, Sweden. Count Folke Bernadotte, Hevdig Johnson Allen and Herman Allen appear in Stockholm, Sweden. Liberty Lady: A True Story of Love and Espionage in WWII Sweden by Pat DiGeorge Herman Allen, meanwhile, served as an airman in the war. His B-17 bomber landed off the coast of Sweden on the island of Gotland. He and other airmen were taken to Sweden to be "interned," DiGeorge said. They were treated well but were not permitted to leave the country, she said. At first, Herman Allen was sent to be interned in the northern part of the country. But after about a month, his typing skills landed him a job as a typist at the American legation in Stockholm, DiGeorge said. Inside 'Romantic and Exciting' Stockholm Sweden stayed neutral during the war, making Stockholm an "exciting place to be," DiGeorge said. It was a city where Americans, Britons and Germans all lived as their countries were involved in the conflict. In the nightclubs, everybody would be "talking and trying to see what they could find out," DiGeorge said, adding there were also "lots of spices" and "lots of intrigue." "When my mother went into Stockholm, she wrote that the lights were on," DiGeorge said. "She had come from London where they weren't allowed to have lights on at night. There had been no bombs. Everything was beautiful. People were out on the streets." Herman and Hedvig Allen Meet DiGeorge said her parents met on her father's first day of work at the American legation. "They took him to the American legation—today it would be the embassy—and in the back of it was the intelligence service," she said. "And that was the day he met my mother. He always told us that he took one look at her and he said, 'You're for me.'" The couple had a quick but lovely courtship, she said. They met in August and got married in January. As their romance blossomed, Herman Allen continued work at the American legation, where he would debrief internees to try to identify spies, she said. During that time, he met the head of American counterespionage in Sweden, a man named Bill Carlson. Carlson asked him to befriend a Swede suspected of selling secrets to Germany. He did just that and gathered enough information to secure his arrest. But the U.S. government decided it was best to have Herman Allen return to the United States for his protection—meaning the couple would need to separate. A Whirlwind Romance and Wedding Facing a return to the U.S., the couple decided to bring forward their wedding, originally planned for February 1949, to January—with some help from Swedish royalty. Count Folke Bernadotte, the nephew of Sweden's King Gustav V and a colleague of Herman Allen, helped arrange a ceremony for the couple before he had to depart, at the city's historic Gustav Adolf Church. They wed on January 18, 1945, DiGeorge said. Herman and Hevdig Allen get married in Stockholm, Sweden. Herman and Hevdig Allen get married in Stockholm, Sweden. Liberty Lady: A True Story of Love and Espionage in WWII Sweden by Pat DiGeorge "It was, I'm sure, the event of the season," she said. "It hit the newspapers the next day, the Swedish newspapers, with a picture of Count Bernadotte. I've been to the church twice. It's really lovely." Her father then returned to the U.S. because his role in the spy case could serve as a "distraction," as nobody was supposed to know the American legation was engaged in intelligence efforts, she said. "No one was supposed be a spy in neutral Sweden, so everything had to be done underground," she said. "It was never supposed to be talked about, but of course everyone knew." Hedvig Allen Remains in Sweden Her father returned to the U.S., but Hedvig Allen stayed in Sweden for work for several months. The couple communicated by "beautiful letters," DiGeorge said. She stayed in Europe through Victory in Europe Day—May 8, 1945. However, Hedvig Allen would soon return to the U.S. herself—because she was pregnant with DiGeorge. The Allens Settle in Florida After the war, the couple settled in Bartow, Florida, where her father remained in charge of cadets at the local air base, DiGeorge said, recounting how her mother described the transition as a shock—going from the cold, northern city of Stockholm to the warmer, humid U.S. state. "They made a good life," she said. "They had five children and then moved to Columbia, South Carolina, in the late '60s and were there until they retired and passed on." DiGeorge said that researching her parents' story was the "most fun" she's ever had. It took her to Sweden twice as well as the National Archives and the Air University Library in Montgomery, Alabama. "It was a beautiful love story with a big family they left behind," she said. "I wish I could tell my mother about everything that's happened since their story came out. She would be so surprised."
Time of India
08-07-2025
- Health
- Time of India
Understanding hypocalcemia: Causes and symptoms of low calcium levels
Calcium is a vital mineral that plays a crucial role in various bodily functions. It's essential for building strong bones, enabling muscle movement, nerve function, blood clotting, and heart health. Calcium is stored primarily in bones, but it's also needed in the blood to facilitate these functions. Inadequate dietary calcium can lead to calcium being drawn from bones, weakening them over time. Calcium deficiency occurs when the level of calcium in the blood is too low; it is referred to as Hypocalcemia. This condition can cause muscle aches, fatigue, and potentially serious complications if left untreated. In some cases, calcium deficiency may not exhibit early symptoms, making regular check-ups crucial. By understanding the causes and symptoms, you can take proactive steps to manage your calcium levels. What is calcium, and why is it important for your body? Calcium is essential for strong bones and teeth, as well as various bodily functions, including blood vessel regulation, nerve function, blood clotting, and muscle contractions. The body typically maintains calcium balance through hormones like parathyroid hormone (PTH), calcitonin, and vitamin D. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it legal? How to get Internet without paying a subscription? Techno Mag Learn More Undo What is hypocalcemia? Hypocalcemia is a condition in which calcium levels in the blood are too low, often due to underlying health conditions. Various health conditions can cause it, often resulting from abnormal levels of parathyroid hormone (PTH) or vitamin D. The condition can range from mild to severe and may be temporary or chronic, requiring proper diagnosis and treatment to manage its effects. Treating hypocalcemia is crucial to prevent potential health complications. Who is affected by hypocalcemia? Hypocalcemia can affect individuals of all ages, including infants. According to the Cleveland Clinic, the age of onset often depends on the underlying cause. In infants, hypocalcemia is often linked to genetic disorders, while in other cases, it may be caused by various health conditions or factors that disrupt calcium levels in the blood. Causes of low calcium levels in the body The following conditions can lead to low calcium levels in the blood, causing hypocalcemia. According to reports, the most common causes include: Hypoparathyroidism: Low levels of parathyroid hormone (PTH) due to underactive parathyroid glands. Vitamin D deficiency: Insufficient vitamin D, which helps the body absorb calcium. Kidney failure: High phosphorus levels and reduced vitamin D production in the kidneys. Other causes include: Certain medications Pseudohypoparathyroidism (a genetic disorder affecting PTH response) Low magnesium levels (hypomagnesemia) Pancreatitis (inflammation of the pancreas) Rare genetic disorders, such as DiGeorge syndrome. Symptoms of hypocalcemia Mild hypocalcemia may not exhibit noticeable symptoms. However, according to the Cleveland Clinic, as the condition progresses, symptoms can include: Muscle cramps, especially in the back and legs Dry, scaly skin Brittle nails Coarse hair If left untreated, hypocalcemia can lead to more severe symptoms, such as: Neurological symptoms: Confusion, memory problems, irritability, restlessness, depression, and hallucinations Severe symptoms: Tingling in lips, tongue, fingers, and feet, muscle aches, spasms, tetany, seizures, abnormal heart rhythms, and congestive heart failure. Early detection and treatment can help manage symptoms and prevent complications. Treating and preventing calcium deficiency The best way to address a calcium deficiency is through dietary changes, incorporating calcium-rich foods such as: Dairy products (milk, cheese, yogurt) Beans Figs Broccoli Tofu Fortified cereals Nuts and seeds (almonds, sesame seeds) For vegans, options include fortified plant-based milk, tofu, and leafy greens like kale and spinach. If supplements are needed, consult a doctor to avoid excessive intake, which can lead to hypercalcemia and related health issues. A healthcare professional will determine the best course of treatment. Calcium blood test A calcium blood test assesses the amount of calcium in your blood. According to WebMD, for adults, the typical normal range for calcium is 8.5 to 10.2 mg/dL (2.15 to 2.55 mmol). Reference ranges can vary among laboratory reference ranges. Calcium levels are typically slightly higher in children and adolescents. The test can establish a diagnosis of hypercalcemia, or high calcium levels, and hypocalcemia, or low calcium levels, and aid health care providers in considering what may be causing the elevated or decreased calcium levels. Diagnosing hypocalcemia To help identify the cause of hypocalcemia, healthcare professionals may order the following tests: Calcium blood test: This test measures calcium in the blood. Other blood tests: Tests may check magnesium, phosphorus, parathyroid hormone (PTH), and vitamin D blood levels. Electrocardiogram (EKG): A test that looks at the heart rhythm to assess for potential problems. Bone imaging tests: Takes a look at calcium problems in the bones, such as osteomalacia or rickets. Also read | Health benefits of Vitamin B6 for your body and how to avoid deficiency
Yahoo
25-06-2025
- Business
- Yahoo
22q11.2 Deletion Syndrome Market Research Report 2025: Zynerba Pharmaceuticals is at the Forefront with Its Clinical-stage Therapy Zygel (ZYN002)
22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a genetic disorder caused by a chromosome 22 deletion, presenting symptoms like heart defects, immune deficiencies, and developmental delays. Market growth is driven by advancements in diagnostic technologies like next-generation sequencing (NGS) and chromosomal microarray analysis (CMA), enabling early detection and tailored interventions. Despite the lack of a cure, targeted therapies, such as Zynerba Pharmaceuticals' Zygel, are emerging. Increased awareness, research funding, and strategic collaborations are enhancing patient care and shaping a promising future for the 22q11.2 deletion syndrome market. Dublin, June 25, 2025 (GLOBE NEWSWIRE) -- The "22q11.2 Deletion Syndrome Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to global 22q11.2 deletion syndrome market is witnessing significant growth, fueled by several key factors. Advancements in diagnostic technologies, such as next-generation sequencing (NGS) and chromosomal microarray analysis (CMA), have improved the accuracy of diagnosis and enabled earlier identification of the condition, leading to more timely interventions and better patient outcomes. Increased awareness and recognition of 22q11.2 deletion syndrome as one of the most common genetic disorders have also contributed to improved diagnosis and greater research development of targeted therapies, such as Zynerba Pharmaceuticals' Zygel (ZYN002) for neuropsychiatric symptoms is further driving 22q11.2 deletion syndrome market growth by offering potential solutions to address the syndrome's complex symptoms. Additionally, the rising investment in rare disease research and the creation of multidisciplinary care models are improving patient care, fostering better long-term health outcomes, and stimulating demand for treatments. Together, these trends are fueling substantial growth in the 22q11.2 deletion syndrome market, offering hope for more effective management and care of individuals affected by 22q11.2 deletion of the significant drivers of the 22q11.2 Deletion Syndrome market is the advancements in diagnostic technologies. The adoption of next-generation sequencing (NGS) and chromosomal microarray analysis (CMA) has greatly improved the accuracy and speed of diagnosing 22q11.2 deletion syndrome. Early and accurate diagnosis allows for timely interventions, which can significantly improve patient outcomes by enabling targeted treatments and personalized care. This growth in diagnostic capabilities has led to increased awareness, more patients seeking treatment, and a greater demand for effective therapies, thereby driving the overall market the growth trajectory, several challenges continue to impact the global 22q11.2 deletion syndrome market. One of the most significant barriers is the lack of curative treatments for the syndrome. Currently, there are no definitive cures, and treatment mainly focuses on managing the symptoms, which can vary widely among individuals. This symptom-based approach can lead to long-term healthcare needs and higher overall treatment the complexity of the syndrome, with its diverse manifestations affecting different organ systems, makes it difficult to develop a one-size-fits-all therapeutic solution. Another challenge is the limited awareness of 22q11.2 deletion syndrome among healthcare providers, which can result in delayed diagnosis and suboptimal improvements in diagnostic technologies, the condition is often misdiagnosed or underdiagnosed, further delaying treatment. These factors contribute to the ongoing hurdles in advancing treatment accessibility and improving patient outcomes in the 22q11.2 deletion syndrome players in the global 22q11.2 deletion syndrome market are significantly shaping the industry with their innovative research and therapeutic developments. Zynerba Pharmaceuticals is at the forefront with its clinical-stage therapy Zygel (ZYN002), a transdermal cannabidiol gel that targets neuropsychiatric symptoms associated with the syndrome. The company is conducting ongoing clinical trials, which offer hope for more effective symptom the 22q11.2 deletion syndrome market evolves, several emerging trends are significantly shaping its future. Advancements in genetic testing, such as next-generation sequencing (NGS) and chromosomal microarray analysis (CMA), are enabling more accurate and earlier diagnoses, which facilitates timely interventions and boosts the demand for targeted therapies. These therapies represent a shift toward personalized and precision medicine, offering more tailored treatment options. Additionally, there is an increase in investment in rare disease research, fueling innovations in diagnostics, treatment options, and patient collaborations between pharmaceutical companies, academic institutions, and healthcare providers are accelerating progress in understanding the syndrome and developing comprehensive care solutions. Furthermore, the expansion of genetic screening programs, particularly newborn screening, is helping to identify 22q11.2 deletion syndrome earlier, leading to better outcomes through early intervention. These trends collectively point to a promising future for the 22q11.2 Deletion Syndrome market, with advancements in diagnostics, personalized care, and treatment options driving growth and improved patient Topics Covered: Executive SummaryScope and DefinitionMarket/Product DefinitionInclusion and ExclusionKey Questions AnsweredAnalysis and Forecast Note1. Global 22q11.2 Deletion Syndrome Markets: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Epidemiology Analysis1.5 Clinical Trial Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global 22q11.2 Deletion Syndrome Market, by Region, ($Million), 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America 22q11.2 Deletion Syndrome Market, by Country2.1.3.1.1 U.S.2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe 22q11.2 Deletion Syndrome Market, by Country2.2.3.1.1 Germany2.2.3.1.2 U.K.2.2.3.1.3 France2.2.3.1.4 Italy2.2.3.1.5 Spain2.2.3.1.6 Rest-of-Europe2.3 Asia Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia Pacific 22q11.2 Deletion Syndrome Market, by Country2.3.3.1.1 China2.3.3.1.2 Japan2.3.3.1.3 Rest-of- Asia Pacific2.4 Rest of the World2.4.1 Key Findings2.4.2 Market Dynamics2.4.3 Market Sizing and Forecast3. Global 22q11.2 Deletion Syndrome Market: Competitive Landscape and Company Profiles3.1 Key Strategies and Development3.1.1 Mergers and Acquisitions3.1.2 Synergistic Activities3.1.3 Business Expansions and Funding3.1.4 Product Launches and Approvals3.1.5 Other Activities3.2 Company Profiles3.2.1 Zynerba Pharmaceuticals3.2.1.1 Overview3.2.1.2 Top Products / Product Portfolio3.2.1.3 Target Customers/End-Users3.2.1.4 Key Personnel3.2.1.5 Analyst View3.2.1 Other Companies4. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
